Literature DB >> 17925193

Cancer-associated bone disease.

Sue A Brown1, Theresa A Guise.   

Abstract

Patients with cancer are at risk for many events involving the skeleton, including metastatic disease of bone and treatment-related bone loss. Cancer-related therapies that can affect bone include hormonal therapy, chemotherapy, and the use of glucocorticoids. Screening for bone loss, with lifestyle modifications and the early use of anti-osteoporosis therapies such as bisphosphonates, may decrease bone loss and reduce the risk of fracture. This article reviews risk factors and mechanisms associated with cancer-related bone loss and metastases as well as strategies for the detection of bone-related complications of cancer and therapies to treat these complications. This article focuses on the more common cancers with adverse skeletal effects: breast cancer, prostate cancer, and multiple myeloma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17925193     DOI: 10.1007/s11914-007-0027-8

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN: 1544-1873            Impact factor:   5.096


  52 in total

1.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Authors:  Victor G Vogel; Joseph P Costantino; D Lawrence Wickerham; Walter M Cronin; Reena S Cecchini; James N Atkins; Therese B Bevers; Louis Fehrenbacher; Eduardo R Pajon; James L Wade; André Robidoux; Richard G Margolese; Joan James; Scott M Lippman; Carolyn D Runowicz; Patricia A Ganz; Steven E Reis; Worta McCaskill-Stevens; Leslie G Ford; V Craig Jordan; Norman Wolmark
Journal:  JAMA       Date:  2006-06-05       Impact factor: 56.272

2.  Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer.

Authors:  Juan Morote; Jacques Planas Morin; Anna Orsola; Jose M Abascal; Carles Salvador; Enrique Trilla; Carles X Raventos; Lluis Cecchini; Gloria Encabo; Jaume Reventos
Journal:  Urology       Date:  2007-03       Impact factor: 2.649

Review 3.  Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.

Authors:  Martha Q Lacy; Angela Dispenzieri; Morie A Gertz; Philip R Greipp; Kimberly L Gollbach; Suzanne R Hayman; Shaji Kumar; John A Lust; S Vincent Rajkumar; Stephen J Russell; Thomas E Witzig; Steven R Zeldenrust; David Dingli; P Lief Bergsagel; Rafael Fonseca; Craig B Reeder; A Keith Stewart; Vivek Roy; Robert J Dalton; Alan B Carr; Deepak Kademani; Eugene E Keller; Christopher F Viozzi; Robert A Kyle
Journal:  Mayo Clin Proc       Date:  2006-08       Impact factor: 7.616

4.  Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane.

Authors:  S Gonnelli; A Cadirni; C Caffarelli; R Petrioli; A Montagnani; M B Franci; B Lucani; G Francini; R Nuti
Journal:  Bone       Date:  2006-08-14       Impact factor: 4.398

5.  Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years.

Authors:  Valentina Guarneri; Sara Donati; Massimiliano Nicolini; Simona Giovannelli; Roberto D'Amico; Pier Franco Conte
Journal:  Oncologist       Date:  2005 Nov-Dec

6.  Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.

Authors:  Michael F X Gnant; Brigitte Mlineritsch; Gero Luschin-Ebengreuth; Stephan Grampp; Helmut Kaessmann; Marianne Schmid; Christian Menzel; Jutta Claudia Piswanger-Soelkner; Arik Galid; Martina Mittlboeck; Hubert Hausmaninger; Raimund Jakesz
Journal:  J Clin Oncol       Date:  2006-12-11       Impact factor: 44.544

7.  The components of excess mortality after hip fracture.

Authors:  J A Kanis; A Oden; O Johnell; C De Laet; B Jonsson; A K Oglesby
Journal:  Bone       Date:  2003-05       Impact factor: 4.398

8.  Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

Authors:  T J Powles; T Hickish; J A Kanis; A Tidy; S Ashley
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544

9.  Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

Authors:  M Dror Michaelson; Donald S Kaufman; Hang Lee; Francis J McGovern; Philip W Kantoff; Mary Anne Fallon; Joel S Finkelstein; Matthew R Smith
Journal:  J Clin Oncol       Date:  2007-03-20       Impact factor: 44.544

10.  Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026].

Authors:  Trevor Powles; Alexander Paterson; Eugene McCloskey; Phil Schein; Bobbi Scheffler; Alwynne Tidy; Sue Ashley; Ian Smith; Lars Ottestad; John Kanis
Journal:  Breast Cancer Res       Date:  2006-03-15       Impact factor: 6.466

View more
  9 in total

1.  Prevalence of osteoporosis among cancer patients in Germany: prospective data from an oncological rehabilitation clinic.

Authors:  M Reuss-Borst; U Hartmann; C Scheede; J Weiß
Journal:  Osteoporos Int       Date:  2011-07-14       Impact factor: 4.507

Review 2.  Calcium-sensing receptor in cancer: good cop or bad cop?

Authors:  Bandana Chakravarti; Shailendra Kumar Dhar Dwivedi; Ambrish Mithal; Naibedya Chattopadhyay
Journal:  Endocrine       Date:  2008-11-15       Impact factor: 3.633

Review 3.  Calcium and vitamin D supplementation and loss of bone mineral density in women undergoing breast cancer therapy.

Authors:  Mridul Datta; Gary G Schwartz
Journal:  Crit Rev Oncol Hematol       Date:  2013-08-07       Impact factor: 6.312

Review 4.  Cancer treatment-related bone disease.

Authors:  Sue A Brown; Theresa A Guise
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2009       Impact factor: 1.807

5.  Osteoporotic fracture rates in chronic hemodialysis and effect of heparin exposure: a retrospective cohort study.

Authors:  Hind Harrak; Emilie René; Noor Alsalemi; Naoual Elftouh; Jean-Philippe Lafrance
Journal:  BMC Nephrol       Date:  2020-07-09       Impact factor: 2.388

6.  Bisphosphonate Treatment Ameliorates Chemotherapy-Induced Bone and Muscle Abnormalities in Young Mice.

Authors:  Alyson L Essex; Fabrizio Pin; Joshua R Huot; Lynda F Bonewald; Lilian I Plotkin; Andrea Bonetto
Journal:  Front Endocrinol (Lausanne)       Date:  2019-11-19       Impact factor: 5.555

7.  Mechanical suppression of breast cancer cell invasion and paracrine signaling to osteoclasts requires nucleo-cytoskeletal connectivity.

Authors:  Xin Yi; Laura E Wright; Gabriel M Pagnotti; Gunes Uzer; Katherine M Powell; Joseph M Wallace; Uma Sankar; Clinton T Rubin; Khalid Mohammad; Theresa A Guise; William R Thompson
Journal:  Bone Res       Date:  2020-11-17       Impact factor: 13.567

8.  Differential impact of adenosine nucleotides released by osteocytes on breast cancer growth and bone metastasis.

Authors:  J Z Zhou; M A Riquelme; X Gao; L G Ellies; L Z Sun; J X Jiang
Journal:  Oncogene       Date:  2014-05-19       Impact factor: 9.867

9.  Osteocytic connexin hemichannels suppress breast cancer growth and bone metastasis.

Authors:  J Z Zhou; M A Riquelme; S Gu; R Kar; X Gao; L Sun; J X Jiang
Journal:  Oncogene       Date:  2016-04-04       Impact factor: 9.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.